ThromboGenics, Inc., President and Global Head of Corporate Development
David Pearson, Ph.D., MBA, is an accomplished biopharmaceutical industry executive with more than 25 years of senior management experience in technical, operational and general management roles. His passion has been the creation of innovative solutions to business, competitive and team challenges, while bridging the R&D, commercial and international worlds.
From 1985 – 2001 David held various management positions in the US and internationally with Novartis, including 8 years in the Swiss headquarters. He was responsible for launching several new products globally and in local markets. From 2002-2003, David was CEO of a German biotechnology company. After 17 years abroad, he returned to the US and has led several early stage companies specializing in ophthalmology, medicinal chemistry and dermatology in Southern California.
David began working with ThromboGenics in September 2010, identifying strategies for commercialization of JETREA® (ocriplasmin) in the US and EU. He led the company’s effort to secure an ex-US partner, which resulted in the selection of Alcon early in 2012. The ThromboGenics and Alcon teams received the Scrip Deal of the Year Award for 2012. As Head of Country Operations, David led the building of ThromboGenics’ US operations, growing the company to 95 employees and launching Jetrea in January 2013. Most recently, David has become Global Head of Corporate Development and continues to serve as President of ThromboGenics, Inc.
David holds a BA in biochemistry and French from Rice University, a PhD in molecular biophysics and biochemistry from Yale University and an MBA from the MIT Sloan School.